10-Year Effectiveness And Safety Of Trabecular Micro-Bypass Stent Implantation With Cataract Surgery In Patients With Primary Open Glaucoma Or Ocular Hypertension

Published 2024 - 42nd Congress of the ESCRS

Reference: FP03.02 | Type: Free paper | DOI: 10.82333/z3qt-qe54

Authors: Tobias H Neuhann FEBOS-CR* ¹ , Raphael Neuhann FEBO ¹

¹Augenklinik am Marienplatz,Ophthalmologikum® Dr.Neuhann,Muenchen,Germany

Purpose

To evaluate ten-year results of implanting one iStent trabecular micro-bypass stent during cataract surgery in eyes with open-angle glaucoma (POAG) or ocular hypertension.

Setting

Multi-specialty German ophthalmology clinic (Augenklinik am Marienplatz, Ophthalmologikum®Dr.Neuhann, Munich, Germany).

Methods

This retrospective, non-randomized case series evaluates iStent trabecular micro-bypass stent implantation with cataract surgery completed by one surgeon over four years in eyes with OAG [including primary OAG (POAG) and pseudoexfoliative glaucoma (PXG)] or ocular hypertension. Study visits were conducted preoperatively and at 2.5 years, 3 years, 5 years, and 10 years postoperatively; examinations included intraocular pressure (IOP), medications, corrected-distance visual acuity, complications, and adverse events.

Results

A total of 63 eyes of 45 patients with OAG (n=60 eyes) or ocular hypertension (n=3 eyes) and data through 10 years were analyzed. Mean preoperative IOP was 18.6 +/- 4.4 mmHg on 1.83 +/-1.03 mean medications. At study visits through 10 years postoperative, mean IOP reduced by 12.8-18.9% (p<0.005 at all points), and mean medication burden reduced by 37.8-51.4% (p≤0.006 at all points). At 10 years postoperatively, 77.8% of eyes had IOP ≤18 mmHg

Conclusions

Significant, sustained, and safe IOP and medication reductions were observed through 10 years postoperative after iStent trabecular micro-bypass stent implantation with cataract surgery in patients with POAG or ocular hypertension.